Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Biophytis SA ( (FR:ALBPS) ).
Biophytis has announced a temporary suspension of the listing of its shares and share warrants on the Euronext Growth and OTC markets due to an upcoming refinancing transaction. This strategic move is expected to impact the company’s financial positioning and operations, with further details to be disclosed when trading resumes, indicating potential implications for stakeholders.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company dedicated to developing drug candidates targeting age-related diseases. Their lead drug candidate, BIO101, is aimed at treating muscular diseases like sarcopenia and Duchenne muscular dystrophy, respiratory diseases such as COVID-19, and metabolic disorders including obesity. The company operates out of Paris, France, with subsidiaries in the USA and Brazil.
YTD Price Performance: 17.14%
Average Trading Volume: 3,540
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €3.07M
Find detailed analytics on ALBPS stock on TipRanks’ Stock Analysis page.
